The global hearing care market offers both general and specific opportunities for continued growth. Our strategy is tuned to capture these benefits while delivering further advances in commercial excellence and operational efficiency. We therefore expect consolidated sales to increase by 8-10% and adjusted EBITA to grow in the range of 12-15% in 2019/20, both measured in local currencies.
| in percentage | Guidance FY 2019/20 |
| Organic sales growth in LC | +7%-9% |
| Net M&A | ca. + 1% |
| Sales growth in local currencies | +8%-10% |
| in percentage | Guidance FY 2019/20 |
| EBITA growth in local currencies | +12%-15% |
* EBITA guidance refers to LC EBITA growth excluding restructuring costs in FY 2018/19, 1H 2019/20 and potential larger restructuring costs going forward; includes expected impact of IFRS 16
While actual reported results may vary based on currency fluctuations, Sonova continues to mitigate the impact of currency fluctuations on earnings growth through its long-term global resource allocation strategy.
Sensitivities*: A strengthening of the USD by 5% would affect sales in the financial year by approximately CHF +45 Mio. and EBITA by approximately CHF +13 Mio. The corresponding effect of a 5% stronger EUR would be CHF +55 Mio. on sales and CHF +25 Mio. on EBITA.